Nonsteroidal anti-inflammatory drugs and the heart

Carlo Patrono, Colin Baigent

Risultato della ricerca: Contributo in rivistaArticolo in rivista

76 Citazioni (Scopus)


Aspirin has been on the market for 115 years. Beginning with the marketing of indomethacin for the treatment of rheumatoid arthritis in 1963, at least 20 other nonsteroidal anti-inflammatory drugs (NSAIDs) with aspirin-like actions have been developed over the past 50 years,1 culminating with the introduction of a new class of selective inhibitors of cyclooxygenase (COX)-2, the coxibs, approximately 15 years ago.2 The NSAIDs represent the single most crowded family of drugs sharing the same therapeutic activities and mechanism of action, perhaps reflecting the unmet therapeutic need in the area of pain management and the large interindividual variability in response to these agents. NSAIDs provide symptomatic relief of pain and inflammation associated with a variety of human disorders, including the rheumatic diseases. Their shared therapeutic actions (ie, analgesic, anti-inflammatory, and antipyretic) are usually accompanied by mechanism-based adverse effects that can, at least in part, be attenuated as a function of individual pharmacokinetic or pharmacodynamic properties.1
Lingua originaleEnglish
pagine (da-a)907-916
Numero di pagine10
Stato di pubblicazionePubblicato - 2014
Pubblicato esternamente


  • anti-inflammatory agents, non-steroidal
  • cyclooxygenase-2 inhibitors
  • heart failure
  • hypertension
  • myocardial infarction
  • stroke


Entra nei temi di ricerca di 'Nonsteroidal anti-inflammatory drugs and the heart'. Insieme formano una fingerprint unica.

Cita questo